The purpose of this study is to investigate the safety and tolerability of three dose strengths of the study drug in subjects with post cataract extraction macular edema.

Inclusion Criteria:

• Have persistent post cataract extraction macular edema whose condition is stable
• Have no change in medication regimen of immunosuppressive or anti-inflammatory agents; steroidal or non-steroidal agents for a specified period of time prior to randomization
• Have at least one eligible eye to be treated in the study
• Have an optical coherence tomography (OCT) scan with a qualifying retinal thickness in the study eye
• Have macular edema confirmed by fluorescein angiography

Exclusion Criteria:

• Have proliferative vitreoretinopathy greater than grade B in either eye
• Have ocular disorders in the study eye that may confound interpretation of study results
• Have ophthalmic disorders in the study eye that may influence final visual acuity and/or fluorescein angiography interpretation
• Have had cataract surgery in the study eye in the past 2 months, YAG laser capsulotomy within the past 1 month, or any other intraocular surgery within the past 90 days
• Have uncontrollable elevated intraocular pressure (IOP) or advanced glaucoma
• Have had any periocular or intravitreal injection of corticosteroids in the study eye within 3 months
• Have had any ocular implant device for the delivery of therapeutic agents
• Be taking any excluded medications that could obscure or confound study results